Alzheimer's disease: Tacrine and tacrine metabolite concentrations in plasma and cognitive change

Authors

  • Kenneth L. Davis,

    1. Department of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    2. Department of Pharmacology, Bronx Veteran's Administration Medical Center, Bronx, New York
    Search for more papers by this author
  • Ren-Kui Yang,

    1. Department of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    Search for more papers by this author
  • Michael Davidson,

    1. Department of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    Search for more papers by this author
  • Richard C. Mohs,

    1. Department of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    Search for more papers by this author
  • Theresa M. Ryan,

    1. Department of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    Search for more papers by this author
  • James Schmeidler,

    1. Department of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    Search for more papers by this author
  • Peter J. Knott,

    Corresponding author
    1. Department of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    2. Department of Pharmacology, Bronx Veteran's Administration Medical Center, Bronx, New York
    3. Department of Neurobiology, Bronx Veteran's Administration Medical Center, Bronx, New York
    • Division of Psychiatry, Department of Veteran's Affairs, 130 West Kingsbridge Road, Bronx, NY 10468
    Search for more papers by this author
  • Leon J. Thal,

    1. The Mount Sinai School of Medicine, New York, and the Division of Psychiatry, Bronx Veteran's Administration Medical Center, Bronx, New York
    2. Department of Neurosciences, University of California, San Diego
    Search for more papers by this author
  • Elkan R. Gamzu

    1. Cambridge NeuroScience Inc., Cambridge, Massachusetts
    Search for more papers by this author

Abstract

In a clinical trial of tacrine in patients with Alzheimer's disease, improvement, measured by changes on both total (ADAST) and the cognitive sub-component (ADASC) of the Alzheimer's Disease Assessment Scale (ADAS) over a 6-week period, correlated significantly with plasma levels of tacrine. Change on the ADAS (both total and the cognitive subcomponent) also correlated significantly with three monohydroxylated metabolites of tacrine 1, hydroxy-tacrine (1-OH-THA), 2, hydroxy-tacrine (2-OH-THA), and 4, hydroxy-tacrine (4-OH-THA). However, changes of the relatively small non-cognitive component of the ADAS were not significantly correlated with plasma levels of tacrine. Multiple correlational analysis revealed that the combined influences of these metabolites were no greater than the effects of tacrine alone in ameliorating the symptoms of Alzheimer's disease. An alternative measure of cognitive performance, the Mini Mental State Exam (MMSE) did not correlate significantly with plasma concentrations of tacrine or its metabolites. Tacrine and these metabolites are bound to plasma proteins. In 10 patients with Alzheimer's disease receiving tacrine, the percentage of tacrine, 1-OH-THA, 2-OH-THA, and 4-OH-THA, that was free in plasma was found to be 19.7 ± 3.3, 51.3 ± 7.7, 40.7 ± 6.9, and 42.4 ± 6.3 (mean ± SD), respectively. © Wiley-Liss, Inc.

Ancillary